The Dendreon bear argument typically revolves around the drug's disappointing sales performance to date, and the competition it's facing in the future. However, one aspect of the bull argument today has nothing to do with sales -- and everything to do with costs.
When revenue growth is hard to come by, taking a hard look at costs is a necessary evil. The company's done just that by right-sizing its manufacturing footprint in order to lower the sales hurdle needed to achieve profitability. A look at Dendreon's current quarter financial sheds light on the opportunity presented by reducing manufacturing costs to below 50% of product sales, a goal it hopes to achieve by the third quarter of 2013.
Even if sales were to remain at current levels, reducing manufacturing costs to 50% would amount to about $13 million in quarterly savings, or about $50 million a year from current levels of about 66% of sales today. Unfortunately, even after achieving that level of cost savings, the company would have a long way to go before breaking even on a cash flow basis, let alone on GAAP earnings.
Even then, investors need to consider the more than $500 million in convertible debt sitting on Dendreon's books. In 2016, the time comes to repay those lenders, and in the absence of some amazing revenue growth the funds are likely to come through a secondary offering.
Resurgence, or dead cat bounce?
Shares of Dendreon have surged in recent months, with the stock gaining new life from the depths of late 2012. Has the company really solved its underlying problems, or are investors setting themselves up for more disappointment? Our new premium research report on Dendreon answers these questions, and many more, while also outlining just how Dendreon intends to regain its former glory. Claim your copy, and a year of free analyst updates, by clicking here now.
Editors Note: A previous version of this article contained a video suggesting that Dendreon could become profitable by cutting manufacturing costs to 50% of product sales. We discovered an error in this analysis, and have removed the video as a result. The Fool regrets the error.
The article Dendreon's Path to Profitability originally appeared on Fool.com.Brenton Flynn has no position in any stocks mentioned. The Motley Fool owns shares of Dendreon. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.